Grace Therapeutics announced a $10 million private placement to support manufacturing and regulatory work for its clinical-stage drug GTx-104, aimed at treating aneurysmal Subarachnoid Hemorrhage (aSAH). The financing, priced at $2.10 per share, is expected to close on August 6, 2026, and extend the company's cash runway to the end of 2028. The company is also implementing a dual-source manufacturing strategy to mitigate risks and expedite FDA approval. This funding is crucial for advancing GTx-104, which offers a novel IV infusion treatment potentially improving outcomes for aSAH patients.
Berlin's state government refused to pay a 30 Bitcoin ransom (about $2.4 million) demanded by the Rhysida ransomware group, leading to the release of 5.7 terabytes of stolen data on the dark web. The cyberattack, detected on August 14, disrupted two ...
Bitcoin traded near $79,972, up 0.43% in 24 hours, with optimism for reaching $85,000 fueled by strong ETF inflows and bullish market sentiment. The global crypto market cap rose to $2.72 trillion, led by gains in Solana, Ethereum, XRP, and BNB. Key ...
OPEC+ decided to keep its oil production unchanged for October, awaiting a full review of member capacities before setting new 2027 quotas. The ongoing Iran war disrupts exports through the Strait of Hormuz, limiting OPEC+'s ability to meet productio...
Dogecoin has surged past its 200-day moving average, approaching the key $0.10 resistance level after a strong rally from around $0.08. This breakout strengthens its short-term bullish outlook, with technical patterns suggesting potential further gai...
Veteran trader Peter Brandt has revived his 2019 Bitcoin logarithmic chart forecast as BTC trades above $80,000, nearing $82,000 resistance. The model suggests Bitcoin's long-term parabolic uptrend remains intact despite the market's evolution, inclu...
